Abstract Oral fluid (OF) offers a noninvasive sample collection for drug testing. However, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) in OF has not been adequately characterized in comparison to plasma. We administered oral low-dose (1.0 mg/kg) and high-dose (1.6 mg/kg) MDMA to 26 participants and collected simultaneous OF and plasma specimens for up to 143 h after dosing. We compared OF/plasma (OF/P) ratios, time of initial detection (t first ), maximal concentrations (C max ), time of peak concentrations (t max ), time of last detection (t last ), clearance, and 3,4-methylenedioxyamphetamine (MDA)-to-MDMA ratios over time. For OF MDMA and MDA, C max was higher, t last was later, and clearance was slower compared to plasma. For OF MDA only, t first was later compared to plasma. Median (range) OF/P ratios were 5.6 (0.1-52.3) for MDMA and 3.7 (0.7-24.3) for MDA. OF and plasma concentrations were weakly but significantly correlated (MDMA: R 2 = 0.438, MDA: R 2 = 0.197, p < 0.0001). Median OF/P ratios were significantly higher following high dose administration: MDMA low = 5.2 (0.1-40.4), high=6.0 (0.4-52.3, p<0.05); MDA low=3.3 (0.7-17.1), high=4.1 (0.9-24.3, p<0.001). There was a large intersubject variation in OF/P ratios. The MDA/MDMA ratios in plasma were higher than those in OF (p<0.001), and the MDA/MDMA ratios significantly increased over time in OF and plasma. The MDMA and MDA concentrations were higher in OF than in plasma. OF and plasma concentrations were correlated, but large inter-subject variability precludes the estimation of plasma concentrations from OF.
Introduction
Sympathomimetic amine stimulants are among the most common illicit drugs in the world. Worldwide, an estimated 11-28 million people aged 15-64 years consumed 3,4-methylenedioxymethamphetamine (MDMA) or its analogs in 2011 [1] . In 2011, 12 % of 19-to 30-year-old Americans and 8 % of 12th graders reported ever trying "ecstasy," while past year use is 5 % for 12th graders and 2 % for 19-to 30-year-olds. The 2007 National Roadside Survey of Alcohol and Drug Use by Drivers detected overall stimulants in 3.3 % of nighttime drivers' oral fluid (OF) or blood [2] , second in prevalence to cannabis. In Victoria, Australia, MDMAwas detected in 0.8 % of injured drivers at a 20-μg/L cutoff in blood [3] .
OF is gaining importance in drug testing, including in drug treatment, workplace, pain management, and driving under the influence of drugs (DUID) settings because collection is noninvasive, easily observed, and has little potential for adulteration. Recently, we documented MDMA and metabolite pharmacokinetics in expectorated OF following controlled oral 1.0 and 1.6 mg/kg MDMA administration in 29 MDMA users [4] . Only MDMA and its metabolite 3,4-methylenedioxyamphetamine (MDA) were identified in OF; 4-hydroxy-3-methoxymethamphetamine (HMMA) and 4-hydroxy-3-methoxyamphetamine (HMA) metabolites were not detected. MDMA appeared to inhibit its own metabolism with a much higher median C max for the high 1.6-mg/kg dose than the lower 1.0-mg/kg dose in proportion to the dose ratio. Median t 1/2 was longer for the high-dose (7.4 h) than the low-dose (4.6 h) MDMA. OF MDMA and MDA concentrations should be greater than plasma concentrations due to the lower pH of OF compared to plasma, leading to ion trapping of the basic drug in OF.
We previously published MDMA plasma pharmacokinetics for 17 subjects [5] . Here, we provide data for 26 participants, enabling additional testing of the differences between low and high doses of MDMA, as well as the time course of OF/P ratios after controlled oral dosing.
There are few data on MDMA OF/P ratios; only two controlled administration studies and one self-administration study provide OF/P ratios and a comparison of OF and plasma pharmacokinetics [6] [7] [8] [9] . However, these studies only documented OF/P ratios up to 24 h after dosing, when the average OF concentration was 126.2 μg/L, and the time of last detection could not be compared between OF and plasma [9] .
We evaluated OF and plasma MDMA and metabolite concentrations in 26 participants following controlled oral low-dose (1.0 mg/kg) and high-dose (1.6 mg/kg) MDMA administration for up to 143 h after dosing to compare the time of initial detection, peak concentrations, and duration of detection. These data will improve OF MDMA interpretation in clinical, drug treatment, law enforcement, and workplace drug testing programs.
Materials and methods

Reagents
Racemic mixtures of AMP-d0, MAMP-d0, MDMA-d0, MDA-d0, MDEA-d0, HMMA-d0 (plasma analysis), AMPd11, MAMP-d14, MDMA-d5, MDA-d5, and MDEA-d6 were obtained from Cerilliant Corp. (Round Rock TX). Racemic HMMA-d0 (OF analysis) and HMA-d0 were purchased from Lipomed, Inc. (Cambridge, MA); p-hydroxymethamphetamine (pholedrine), ACS reagent grade Tris [hydroxymethyl] aminomethane base, Tris [hydroxymethyl] aminomethane hydrochloride, triethylamine (99.5 % purity), and GC grade n-heptane were from Sigma (St. Louis, MO). ACS reagent grade monobasic and dibasic potassium phosphate, hydrochloric acid (HCl), sodium hydroxide, acetic acid, isopropanol, ammonium hydroxide, and ethyl acetate (HPLC grade) were purchased from JT Baker (Phillipsburg, NJ). HPLC grade methanol was obtained from Fisher Scientific and heptafluorobutyric acid anhydride (HFAA) from Pierce Chemical Co. (Rockford, IL). Styre Screen™ DBX solid phase extraction (SPE) columns and fritted filters (10 µm pore, 4-mL reservoir volume) used in preparing oral fluid samples for solid phase extraction were purchased from United Chemical Technologies (Bristol, PA). SPEC C18AR/MP1, 3-mL reservoir/30-mg bed mass, mixed mode monolithic silica disc solid phase extraction columns were purchased from Varian Inc. (Lake Forest, CA).
Human participants
Healthy male and female participants provided written informed consent for this National Institute on Drug Abuse Intramural Research Program Institutional Review Board-approved study. Participants were recruited by television, radio and newspaper advertisements, flyers, and word of mouth; provided written informed consent; and were compensated for their time and inconvenience. The inclusion criteria were 18-40 years of age, lifetime consumption of at least five tablets of ecstasy, and at least one in the 90 days prior to screening. Female participants were required to utilize a reliable form of birth control or abstain from sexual intercourse throughout the study. A serum pregnancy test was administered at the screening visit and urine pregnancy tests were performed on the morning of each study session.
All participants received a comprehensive medical and psychological evaluation, including drug use history and physical examination, clinical laboratory tests, 12-lead electrocardiogram with 3-min rhythm strip, Symptom Checklist-90-Revised, and computer-administered screening version of the Structured Clinical Interview for the Diagnostic & Statistical Manual of Mental Disorders IV. The exclusion criteria included: nursing and pregnant women; current medical condition or history of neurological illness, e.g., positive HIV serology test, positive Fluorescent Treponemal Antibody Absorption Test confirmatory test for syphilis, head trauma with loss of consciousness for >3 min, stroke, central nervous system tumor, encephalitis or other CNS infection, multiple sclerosis or other demyelinating disease, epilepsy, movement disorder, or migraine headaches severe enough to require treatment; current axis I psychiatric diagnosis including drug and alcohol dependence (except nicotine, cannabis or MDMA); recent (within 30 days of MDMA administration) ingestion of a CYP2D6 or CYP3A4 inhibitor or CYP3A4 inducer; systolic blood pressure (BP) >135 mmHg, diastolic BP >85 mmHg, or heart rate >100 bpm after 5-min rest; total cholesterol >250 mg/dL if older than 30 years; hemoglobin <12.5 g/100 mL (male) or <12 g/100 mL (female); clinically significant abnormal electrocardiogram; and serum transaminase levels more than three times the normal.
Study design
Participants had two options for study participation: one continuous 23-day residential stay with three dosing sessions, or three separate residential stays, each with a single dosing session, separated by at least 1 week and completed within a year. At each dosing session, participants ingested either placebo (0 mg/kg), low-dose (1.0 mg/kg), or highdose (1.6 mg/kg) MDMA (Lipomed, Arlesheim, Switzerland) in a randomized, counterbalanced, doubleblind design. Active drug was given as the hydrochloride salt and placebo was given as lactose. Both study medications were packaged in size 0 Torpac® capsules (Fairfield, NJ). A maximum 150-mg dose was given to the two participants (participants P and W) weighing more than 93.75 kg.
Participants entered the residential unit ≥12 h before dosing and remained for 1-7 days after dosing. Urine samples collected at entry were screened for benzodiazepines, cocaine, amphetamines, cannabis, opiates, phencyclidine, and barbiturates with Triage® 7 drugs of abuse panel (Biosite, Inc., San Diego, CA). Negative results were required for all drugs except amphetamines and cannabis. Participants completing the study with separate stays were reevaluated before each stay to verify continued eligibility. The morning after admission, participants ate a light breakfast. Females with reproductive potential were given a urine pregnancy test. Baseline measures, biologic specimens, and a 12-lead electrocardiogram were collected. Participants then ingested study medication while seated. Dosing sessions were separated by at least 1 week. After dosing, participants remained seated and were monitored by medical staff for 3 h or until systolic BP, diastolic BP, and heart rate returned to within 20 % of the pre-dose levels (or heart rate to <95 bpm), whichever occurred later. Plasma and expectorated OF were collected at −0.25, 0.25, 0. 
Specimen collection
Whole blood was collected into sodium heparin (green-top) vacutainers and stored on ice up to 2 h. Samples were centrifuged at 4°C at 3,000 rpm for 10 min for the separation of plasma. Samples were stored frozen at −20°C until analysis. OF samples were collected by expectoration into polypropylene tubes.
Plasma analysis
Plasma MDMA, MDA, HMMA, and HMA were quantified according to a previously published two-dimensional GCMS method, with slight modifications [10] . Briefly, 1 mL plasma was diluted with 1 mL 0.5 mol/L HCl and incubated at 100°C for 40 min. After cooling, 1 mL 0.1 mol/L phosphate buffer (pH 6.0) and 50 μL 10 mol/L NaOH was added and the samples centrifuged. Supernatant was decanted onto preconditioned polymeric Styre Screen DBX SPE columns and washed with deionized H 2 0, 0.1 mol/L acetic acid, and methanol. Dried columns were eluted with ethyl acetate/isopropanol/ammonium hydroxide (90:6:4, v/v/v). Methanolic HCl (15 μL, 0.12 mol/L) was added to each extract prior to evaporation under nitrogen at 35°C. Residues were reconstituted in 100 μL 0.5 mol/L triethylamine in heptane and derivatized with 10 μL HFAA at 60°C for 20 min. After cooling, samples were back-extracted with 200 μL phosphate buffer (pH 7.4). The organic layer was injected onto an Agilent 6890 GC configured with a microfluidic Deans switch and flame ionization detector and interfaced to an Agilent 5973 mass selective detector (2D-GCMS). Recoveries were >85 %. Linear ranges were 5-100 μg/L for MDA and HMA and 5-400 μg/L for MDMA and HMMA. R 2 were >0.997, analytical bias was between 85.6 and 107.2 % of target concentration, and the coefficients of variation for inter-assay imprecision were ≤6.7 % for all analytes (n=20 for each analyte).
Oral fluid analysis
Expectorated OF MDMA, MDA, HMMA, and HMA were quantified according to a previously published GCMS method [11] , with a few modifications. Briefly, expectorated OF was centrifuged at 2,000×g for 6 min. A 400-μL aliquot was transferred to a 10-μm fritted filter reservoir inside a glass test tube. Samples were vortexed, diluted with 2 mL 0.1 M potassium phosphate buffer (pH 6.0), and centrifuged through filters at 1,000×g for 5 min. Filtrates were decanted onto preconditioned SPEC C18AR/MP1 columns and washed with acetic acid and methanol. Dried columns were eluted with ethyl acetate/methanol/ammonium hydroxide (78:20:2, v/v/v). Methanolic HCl (15 μL, 0.12 mol/L) was added to each extract prior to evaporation under nitrogen at 35°C. Residues were reconstituted in 100 μL 0.05 mol/L triethylamine in heptane and derivatized with 10 μL HFAA at 60°C for 20 min. After cooling, 200 μL 0.05 M Tris buffer (pH 7.4) was added and the organic layer injected onto the GCMS.
The injection volume was reduced to 1 μL to prevent saturation of the detector at elevated concentrations without sacrificing signal response at the limit of quantification (LOQ). Two calibration curves, utilizing a 1/x 2 weighted least-squares model, were established to encompass the wide range of drug concentrations. Low linear ranges were 5-500 μg/L for MDMA and MDA and 10-500 μg/L for HMA and HMMA; high linear ranges were 500-4000 μg/L for all analytes. R 2 were >0.993 and recoveries were >85 %. Analytical bias was 87.1-104.0 % of the target concentration, and the coefficients of variation for inter-assay imprecision were ≤6.8 % for all analytes (n=24 for each analyte).
Data analysis
Statistical analyses were conducted with SPSS 13.0 for Windows. Visual inspection of data and evaluation by Kolmogorov-Smirnov tests indicated non-normal data distribution. Non-compartmental maximal concentration (C max ), time to maximal concentration (t max ), half-life (t 1/2 ), time of first detection (t first ), time of last detection (t last ), clearance, as well as the MDA/MDMA ratios, were compared with the Wilcoxon signed-rank test. Cutoffs utilized for MDMA t last included the analytical limit of quantification (5 μg/L), the Talloires cutoff (20 μg/L), the DRUID (Driving Under the Influence of Drugs, Alcohol and Medicines) cutoff (25 μg/L), and the proposed SAMHSA (Substance Abuse and Mental Health Services Administration) cutoff (50 μg/L) [12] [13] [14] . There are no defined cutoffs for MDA; therefore, the evaluated cutoffs were 10 and 20 μg/L. Higher cutoffs of 25 and 50 μg/L were not evaluated for MDA because the MDA plasma concentrations never exceeded these cutoffs. Least-squares regression analysis in Prism version 5.02 (Graphpad Software Inc.) was employed to evaluate the concentrations and the MDA/MDMA ratios. The OF/P ratios for MDMA and metabolites were determined in simultaneously collected specimens. The OF/P ratios were only calculated at time points when analytes were quantifiable in both matrices. The dose effects on OF/P were evaluated using MannWhitney tests. Significance was attributed at p<0.05 (twotailed) for all statistical tests.
Results
Human participants
Twenty-six volunteers (16 men, 10 women) ages 18-35 years participated in the study ( [4, 5] . Only eight participants with a continuous 23-day stay are considered in this comparison. There were significant differences between plasma and OF for C max , t last , and clearance for MDMA (Table 2) and for t first , C max , t last , and clearance for MDA (Table 3) . For the eight participants with a 23-day stay, the OF MDMA and MDA concentrations were approximately tenfold those of plasma and closely paralleled the plasma concentrations over time (Fig. 2) . While there was a large inter-subject variation, the median OF/P ratios varied over time, peaking 1.3-2.5 h after oral MDMA administration. Fewer OF samples were collected immediately after MDMA dosing due to reduced salivary flow after psychostimulant administration.
Buccal contamination appeared to occur in one participant's samples after both low-and high-MDMA administrations. This individual was not one of the 23-day stay participants; thus, his data were not included in the t first determination. The MDMA OF concentrations were 6,507 and 7,676 μg/L at 0.25 h after the low and high doses, but dropped to 766 μg/L (low) and 407 μg/L (high) at 0.75 and 1.25 h, respectively, and increased thereafter. The MDMA in this participant was not detected in plasma samples until 0.75 and 2 h after the low and high doses. MDMA was not detected in baseline OF samples and MDA was not detected in MDMA-positive 0.25-h OF samples. It is possible that the participant cracked open the capsule before swallowing. Because MDMA was not detected in the first two corresponding plasma samples, these data were not included in the OF/P ratio results.
Metabolite-to-parent analyte ratios
In the eight 23-day stay participants, the MDA/MDMA ratios significantly increased over time in both matrices ( Fig. 3) : R 2 between the MDA/MDMA ratios and time were 0.87, 0.92, 0.88, and 0.94 for plasma (low), plasma (high), OF (low), and OF (high), respectively (all p<0.0001). The MDA/MDMA ratios in OF were correlated with those in plasma (R 2 = 0.97, p < 0.001). However, the MDA/MDMA ratios in plasma were higher than those in OF (p<0.001; Fig. 3 ). The lower sample numbers at the start and end of the time course were due to reduced salivary flow following psychostimulant ingestion yielding low OF volume and lack of detection of concomitant MDMA and MDA at later time points, respectively.
Discussion
We present a thorough examination of the differences in the disposition of MDMA and metabolites in human OF and plasma following controlled oral MDMA administration. This work is the first to document MDA OF/P ratios following MDMA administration. MDMA initially appeared in OF 0.25-1.0 h after dosing and peaked after 1.3-5 h, similar to plasma. However, MDA appeared slightly later in OF compared to plasma. For MDMA and MDA, OF C max was significantly greater than plasma C max . This is not surprising because both MDMA and MDA are basic drugs and are subject to ion trapping in OF due to its lower pH compared to blood. Furthermore, this is evidenced by the large 5.6 median OF/P ratio (0.1-52.3) for MDMA and 3.7 (0.7-24.3) for MDA (Fig. 1) and the higher overall OF concentrations compared to plasma (Fig. 2) , indicating that these drugs partition into OF to a greater extent.
OF and plasma t 1/2 were comparable for MDMA and MDA following low-and high-dose MDMA administration. This is inconsistent with a previous finding that MDMA t 1/2 appeared shorter in OF [9] . However, in that study, no statistical analysis was performed to confirm the shorter t 1/2 in OF. Time of last detection was significantly longer in OF for both MDMA and MDA. However, consideration of plasma HMMA (analytical LOQ=5 μg/L), which was not detected in OF, extended the detection window past that of MDMA in plasma or OF, to 71 h (71-95) and 95 h (71-119) following the low and high doses, respectively. Clearance is significantly faster in plasma than OF for MDMA and MDA (Tables 2 and 3 ). This is most likely due to the ion trapping of the drug in the OF, leading to slow diffusion back into the plasma.
The median overall OF/P ratios were 5.6 (0.1-52.3) for MDMA and 3.7 (0.7-24.3) for MDA, with statistically significant correlations of OF and plasma concentrations. However, the correlations were weak (R 2 =0.44 for MDMA and 0.20 for MDA), with a large inter-subject variability, precluding direct prediction of plasma concentrations from OF levels. Samyn and van Haeren [6] reported OF/P ratios from 1 to 16.5 in nine individuals who self-administered MDMA. Others reported similar OF/P ratios of 0.8-22.4 following controlled administration of 75 mg MDMA in 25 mL orange syrup [7] . A mean±SD maximal OF/P of 12±6 occurred at the first collection 1 h after dosing and dropped to 4±3 by the last collection 4-5 h post-dose. Similar OF/P ratios were documented for the stereoisomers. Following controlled administration, R-(−)-MDMA OF/P ratios were 2.6-46.3, whereas S-(+)-MDMA ratios were 3.5-49.8 [8] . Navarro et al. [9] also reported OF/P ratios of 1.2-32.2, with peak ratios at 1.5 h after a 100-mg MDMA dose. MDMA t max were the same in OF and plasma. The half-life (t 1/2 ) was longer in plasma (7.2 h) compared to OF ratio is consistent with previously reported ratios from other controlled drug administration studies and community cases [6] [7] [8] [9] . We observed a large variation in OF/P ratio, indicating that plasma concentrations cannot be predicted from OF concentrations. Furthermore, the OF/P ratio varied over time, peaking 1.3-2.5 h after MDMA administration. Similar peaks in OF/P ratios were reported elsewhere, occurring 1-1.5 h post-dose, although collection time points were less frequent than in our study [7, 9] . The OF/P ratios were significantly higher following the high (6.0, 0.4-52.3) compared to the low (5.2, 0.1-40.4) MDMA doses. We previously showed that MDMA inhibits its own metabolism [5] . We postulate that the nonlinear pharmacokinetics creates a dynamic concentration gradient and that high MDMA plasma concentrations act to drive MDMA into the more acidic OF. Navarro et al. [9] documented even more acidic OF following MDMA administration due to the lowered salivary flow, as well as a correlation between plasma concentration and the OF/P ratio. The higher plasma concentrations may prolong or exacerbate the lowered OF pH, leading to high drug accumulation in OF after the high dose.
In our study, one participant was suspected of having cracked the capsule prior to swallowing, leading to buccal contamination. Since MDMA is typically found in tablet form, we suspect that oral contamination may occur more frequently with a self-administered drug. This may affect the OF/P ratios for the first hour following drug ingestion.
MDA/MDMA ratios steadily increased over time in OF and plasma. MDA/MDMA in OF paralleled that in plasma, with a strong correlation, but the ratios were significantly lower in OF. The delayed appearance of MDA in OF compared to plasma, the lower OF/P ratios compared to MDMA, and the significantly lower MDA/MDMA ratio in OF compared to plasma all suggest that MDA does not enter the oral cavity as readily as MDMA. The only concomitantly measured MDMA and MDA pK a to our knowledge report conflicting pK a values [15] . MDMA pK a was estimated at 9.9 (derived from methamphetamine) [9] and MDA pK a is 9.67 [16] . The reported logP for MDMA and MDA are 1.68 and 1.38, respectively; the protein-bound fraction is 34-40 % for both [15, 17] . MDMA has a slightly higher pK a than MDA and, thus, should be more ionized in plasma, slightly reducing its ability to cross into the OF. On the other hand, MDMA is more lipophilic than MDA, suggesting that MDMA would distribute more rapidly into the OF. Another factor that could explain the higher relative MDMA concentrations in OF is the 10-to 20-fold greater MDMA concentrations in plasma, yielding a greater concentration gradient and driving factor for MDMA to cross into the OF. The MDA/MDMA ratio time course suggests that ratios might be useful for interpreting time of last use. However, the ratios presented here are based on a single MDMA administration and may not be representative of those after multiple doses. Furthermore, inter-subject variability precludes direct calculation of time of last use.
Conclusion
We document MDMA and MDA appearance in OF after controlled oral MDMA administration. The MDMA and MDA concentrations were much higher in OF compared to plasma. OF and plasma concentrations were correlated, but the large inter-subject variability precludes estimation of plasma concentrations from the OF. Times of last detection were 24-48 h for MDMA and 12-47 h for MDA in OF. These results improve the interpretation of OF tests in DUID cases and workplace and drug treatment programs.
